equityflowunderstand the flow and follow it
EquityFlow › Companies › Apollo Therapeutics

Apollo Therapeutics

Biotech · Cambridge, GB

Biopharma translating university research into medicines.

In the network

Shares the most investors with (number = shared investors):
Nuclera 2

Funding history

DateRoundAmount
Jan 2024Series C
Cambridge biopharma Apollo Therapeutics added $33.5M in a second close of its Series C (now $260M total) led by Patient Square Capital.
$33.5M

Investors

Tap an investor to see what else they have backed.

M&GPatient Square CapitalRock Springs Capital

Other companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca

Other companies in GB

Capsa AI01HealthRem3dy HealthNewOrbitJoyvié HealthFuse EnergyAirspeedSembleWordsmithOxford Quantum CircuitsFreshaImperagen

Other companies at Series C stage

99 Group9finA5XACROVEAI21 LabsAMIATAI Life SciencesAcceldataAccountsIQActiveCampaignAgicapAgomAb Therapeutics
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.